| Year |
Citation |
Score |
| 2020 |
Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, et al. Author Correction: Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports. 10: 3531. PMID 32081980 DOI: 10.1038/S41598-020-58955-Y |
0.322 |
|
| 2019 |
Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM, Jayashankar L, Miotto P, Zignol M, Schito M. Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30883637 DOI: 10.1093/Cid/Ciz219 |
0.409 |
|
| 2018 |
Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, et al. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports. 8: 15382. PMID 30337678 DOI: 10.1038/S41598-018-33731-1 |
0.378 |
|
| 2018 |
Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, ... ... Starks AM, et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. The New England Journal of Medicine. 379: 1403-1415. PMID 30280646 DOI: 10.1056/Nejmoa1800474 |
0.328 |
|
| 2017 |
Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. The European Respiratory Journal. 50. PMID 29284687 DOI: 10.1183/13993003.01354-2017 |
0.375 |
|
| 2016 |
Yakrus MA, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B, Starks AM. Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States. Tuberculosis Research and Treatment. 2016: 3404860. PMID 27375902 DOI: 10.1155/2016/3404860 |
0.385 |
|
| 2015 |
Shak EB, France AM, Cowan L, Starks AM, Grant J. Representativeness of Tuberculosis Genotyping Surveillance in the United States, 2009-2010. Public Health Reports (Washington, D.C. : 1974). 130: 596-601. PMID 26556930 DOI: 10.1177/003335491513000607 |
0.317 |
|
| 2015 |
Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, Gallarda J, Hanna D, Kim PS, Liwski R, Miotto P, Schito M, Zignol M. Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S141-6. PMID 26409275 DOI: 10.1093/Cid/Civ610 |
0.361 |
|
| 2015 |
Yakrus MA, Metchock B, Starks AM. Evaluation of a u.s. Public health laboratory service for the molecular detection of drug resistant tuberculosis. Tuberculosis Research and Treatment. 2015: 701786. PMID 25793126 DOI: 10.1155/2015/701786 |
0.371 |
|
| 2015 |
Salamon H, Yamaguchi KD, Cirillo DM, Miotto P, Schito M, Posey J, Starks AM, Niemann S, Alland D, Hanna D, Aviles E, Perkins MD, Dolinger DL. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. The Journal of Infectious Diseases. 211: S50-7. PMID 25765106 DOI: 10.1093/Infdis/Jiu816 |
0.389 |
|
| 2015 |
Shinnick TM, Starks AM, Alexander HL, Castro KG. Evaluation of the Cepheid Xpert MTB/RIF assay. Expert Review of Molecular Diagnostics. 15: 9-22. PMID 25373876 DOI: 10.1586/14737159.2015.976556 |
0.36 |
|
| 2014 |
Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM. Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. Journal of Clinical Microbiology. 52: 1932-7. PMID 24648563 DOI: 10.1128/Jcm.00417-14 |
0.384 |
|
| 2012 |
Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, Parrish N, Pentella M, Vanneste J, Wang YF, Starks AM. Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems. Journal of Clinical Microbiology. 50: 3275-82. PMID 22837326 DOI: 10.1128/Jcm.01225-12 |
0.308 |
|
| 2011 |
Winston CA, Navin TR, Becerra JE, Chen MP, Armstrong LR, Jeffries C, Yelk Woodruff RS, Wing J, Starks AM, Hales CM, Kammerer JS, Mac Kenzie WR, Mitruka K, Miner MC, Price S, et al. Unexpected decline in tuberculosis cases coincident with economic recession - United States, 2009. Bmc Public Health. 11: 846. PMID 22059421 DOI: 10.1186/1471-2458-11-846 |
0.325 |
|
| 2011 |
Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 55: 2032-41. PMID 21300839 DOI: 10.1128/Aac.01550-10 |
0.369 |
|
| 2009 |
Ngamlert K, Sinthuwattanawibool C, McCarthy KD, Sohn H, Starks A, Kanjanamongkolsiri P, Anek-vorapong R, Tasaneeyapan T, Monkongdee P, Diem L, Varma JK. Diagnostic performance and costs of Capilia TB for Mycobacterium tuberculosis complex identification from broth-based culture in Bangkok, Thailand. Tropical Medicine & International Health : Tm & Ih. 14: 748-53. PMID 19392738 DOI: 10.1111/J.1365-3156.2009.02284.X |
0.347 |
|
| 2009 |
Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 53: 1061-6. PMID 19104018 DOI: 10.1128/Aac.01357-08 |
0.365 |
|
| 2006 |
Starks AM, Bourdage KL, Thiaville PC, Gulig PA. Use of a marker plasmid to examine differential rates of growth and death between clinical and environmental strains of Vibrio vulnificus in experimentally infected mice. Molecular Microbiology. 61: 310-23. PMID 16856938 DOI: 10.1111/J.1365-2958.2006.05227.X |
0.623 |
|
| 2005 |
Gulig PA, Bourdage KL, Starks AM. Molecular pathogenesis of Vibrio vulnificus Journal of Microbiology. 43: 118-131. PMID 15765065 |
0.601 |
|
| 2000 |
Starks AM, Schoeb TR, Tamplin ML, Parveen S, Doyle TJ, Bomeisl PE, Escudero GM, Gulig PA. Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice Infection and Immunity. 68: 5785-5793. PMID 10992486 DOI: 10.1128/Iai.68.10.5785-5793.2000 |
0.629 |
|
| 2000 |
Kwang Cheol Jeong, Hye Sook Jeong, Joon Haeng Rhee, Shee Eun Lee, Sun Sik Chung, Starks AM, Escudero GM, Gulig PA, Sang Ho Choi. Construction and phenotypic evaluation of a Vibrio vulnificus vvpE mutant for elastolytic protease Infection and Immunity. 68: 5096-5106. PMID 10948131 DOI: 10.1128/Iai.68.9.5096-5106.2000 |
0.614 |
|
| Show low-probability matches. |